Nitric oxide (NO)-related pharmaceuticals: Contemporary approaches to therapeutic no modulation

Free Radical Biology and Medicine

Volumn 28, Issue 10, 2000, Pages 1495-1506

  Janero, David R ^a  

^a NitroMed Inc   (United States)

Author keywords

Drug discovery and development; Free radical; Gastrointestinal toxicity; Nitric oxide; Nonsteroidal anti inflammatory drug; Pharmaceuticals; Restenosis; Sexual dysfunction

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SILDENAFIL;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG INDUSTRY; HUMAN; INFLAMMATION; PENIS ERECTION; PRIORITY JOURNAL; RESTENOSIS; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIGESTIVE SYSTEM; DISEASE; DRUG DESIGN; HUMANS; IMPOTENCE; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; WOUNDS AND INJURIES;

EID: 0034656835     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00247-1     Document Type: Conference Paper

References (96)

1. Furchgott R.F., Zawadski J.V. The obligatory role of endothelial cells in the relaxation of arterial muscle by acetylcholine. Nature. 288:1980;373-376.
2. SoRelle R. Nobel Prize awarded to scientists for nitric oxide discoveries. Circulation. 98:1998;2365-2366.
3. Fleming I., Busse R. NO the primary EDRF . J. Mol. Cell. Cardiol. 31:1999;5-14.
4. Patel R.P., McAndrew J., Sellak H., White C.R., Jo H., Freeman B.A., Darley Usmar V.M. Biological aspects of reactive nitrogen species. Biochim. Biophys. Acta. 1411:1999;385-400.
5. Mayer B., Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci. 22:1997;477-481.
6. Marletta M.A., Hurshman A.R., Rusche K.M. Catalysis by nitric oxide synthase. Curr. Opin. Chem. Biol. 2:1998;656-663.
7. Grisham M.B., Jourd'Heuil D., Wink D.A. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites implications in inflammation . Am. J. Physiol. 276:1999;G315-G321.
8. Ewing J.F., Janero D.R., Grinnell T.A., Schroeder J.D., Garvey D.S. Reactivity of nitrogen monoxide species with NADH implications for nitric oxide-dependent posttranslational protein modification . Arch. Biochem. Biophys. 343:1997;131-139.
9. Denninger J.W., Marletta M.A. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta. 1411:1999;334-350.
10. Murad F. Nitric oxide signaling would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Prog. Horm. Res. 53:1998;43-60.
11. Eiserich J.P., Patel R.P., O'Donnell V.B. Pathophysiology of nitric oxide and related species free radical reactions and modification of biomolecules . Mol. Aspects Med. 19:1998;221-357.
12. Koppenol W.H. The basic chemistry of nitrogen monoxide and peroxynitrite. Free Radic. Biol. Med. 25:1998;385-391.
13. Lepoivre M., Flaman J.M., Henry Y. Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. J. Biol. Chem. 267:1992;22994-23000.
14. Wink D.A., Mitchell J.B. Chemical biology of nitric oxide insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide . Free Radic. Biol. Med. 25:1998;434-456.
15. Kröncke K.-D., Fehsel K., Kolb-Bachofen V. Nitric oxide cytoxicity versus cytoprotection - how, why, when, and where? Nitric Oxide Biol. Chem. 1:1997;107-120.
16. Keshive M., Singh S., Wishnok J.S., Tannenbaum S.R., Deen W.M. Kinetics of S-nitrosation of thiols in nitric oxide solutions. Chem. Res. Toxicol. 9:1996;988-993.
17. Cooper C.E. Nitric oxide and iron proteins. Biochim. Biophys. Acta. 1411:1999;290-309.
18. Pryor W.A., Squadrito G.L. The chemistry of peroxynitrite and peroxynitrous acid products from the reaction of nitric oxide with superoxide . Am. J. Physiol. 268:1996;L699-L721.
19. Janero D.R., Hreniuk D., Sharif H.A. Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte); lethal peroxidative membrane injury. J. Cell. Physiol. 149:1991;347-364.
20. Hogg N., Kalyanaraman B. Nitric oxide and lipid peroxidation. Biochim. Biophys. Acta. 1411:1999;378-384.
21. Beck K.F., Eberhardt W., Frank S., Huwiller A., Messmer U.K., Mühl H., Pfeilschifter J. Inducible nitric oxide synthase role in cellular signaling . J. Exp. Biol. 202:1999;645-653.
22. Symeonides S., Balk R.A. Nitric oxide in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13:1999;449-463.
23. Brüne B., von Knethen A., Sandau K.B. Nitric oxide and its role in apoptosis. Eur. J. Pharmacol. 351:1998;261-272.
24. Rosenfeld M.E. Inflammation, lipids, and free radicals lessons learned from the atherogenic process . Semin. Reprod. Endocrinol. 16:1998;249-261.
25. Minning D.M., Gow A.J., Bonaventura J., Braun R., Dewhirst M., Goldberg D.E., Stamler J.S. Ascaris hemoglobin is a nitric oxide-activated "deoxygenase." Nature. 410:1999;497-502.
26. Chabrier P.E., Demerlé Pallardy C., Auget M. Nitric oxide synthases targets for therapeutic strategies in neurological diseases . Cell. Mol. Life Sci. 55:1999;1029-1035.
27. Frieri M. Nitric oxide in allergic rhinitis and asthma. Allergy Asthma Proc. 19:1998;349-351.
28. Thomsen L.L., Miles D.W. Role of nitric oxide in tumor progression lessons from human tumors . Cancer Metastasis Rev. 17:1998;107-118.
29. Janero D.R. Myocardial ischemia-reperfusion injury and the cardioprotective potential of natural antioxidants. Frei B. Natural antioxidants in human health and disease. 1994;411-445 Academic Press, San Diego.
30. Ambrosio G., Tritto I. Reperfusion injury experimental evidence and clinical implications . Am. Heart J. 138:1999;69-75.
31. Jang D., Murrell G.A.C. Nitric oxide in arthritis. Free Radic. Biol. Med. 24:1998;1511-1519.
32. Amin A.R., Attur M., Abramson S.B. Nitric oxide synthase and cyclooxygenases distribution, regulation, and intervention in arthritis . Curr. Opin. Rheumatol. 11:1999;202-209.
33. Muscara M.N., Wallace J.L. Nitric oxide. V. Therapeutic potential of nitric oxide donors and inhibitors. Am. J. Physiol. 276:1999;G1313-G1316.
34. Babu B.R., Griffith O.W. Design of isoform-selective inhibitors of nitric oxide synthase. Curr. Opin. Chem. Biol. 2:1998;491-500.
35. Pihl-Carey K. Medinox moves forward with plan to neutralize NO directly. BioWorld Today. 10:1999;1.
36. McIntyre M., Dominiczak A.F. Nitric oxide and cardiovascular disease. Postgrad. Med. 73:1997;630-634.
37. Arnal J.F., Dinh Xuan A.T., Pueyo M., Darblade B., Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell. Mol. Life Sci. 55:1999;1078-1087.
38. Shulz R., Triggle C.R. Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol. Sci. 15:1994;255-259.
39. Abman S.H., Kinsella J.P. Inhaled nitric oxide therapy for pulmonary disease in pediatrics. Curr. Opin. Pediatr. 10:1998;236-242.
40. Hart C.M. Nitric oxide in adult lung disease. Chest. 115:1999;1407-1417.
41. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27:1996;567-574.
42. Cardillo C., Panza J.A. Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Vasc. Med. 3:1998;138-144.
43. Miyamoto Y., Saito Y., Kajiyama N., Yoshimura M., Shimasaki Y., Nakayama M., Kamitani S., Harada M., Ishikawa M., Kuwahara K., Ogawa E., Hamanaka I., Takahashi N., Kaneshige T., Teraoka H., Akamizu T., Azuma N., Yoshimasa Y., Yoshimasa T., Itoh H., Masuda I., Yasue H., Nakao K. Endothelial nitric oxide synthase gene is positively correlated with essential hypertension. Hypertension. 32:1998;3-8.
44. Vogel R.A. Coronary risk factors, endothelial function, and atherosclerosis a review . Clin. Cardiol. 20:1997;426-432.
45. Mombouli J.V., Vanhoutte P.M. Endothelial dysfunction from physiology to therapy . J. Mol. Cell. Cardiol. 31:1999;61-74.
46. Parrat J.R. Nitroglycerine - the first one hundred years new facts about an old drug . J. Pharm. Pharmacol. 31:1979;801-809.
47. Gordge M.P. How toxic is nitric oxide? Exp. Nephrol. 6:1998;12-16.
48. Ewing J.F., Janero D.R. Specific S-nitrosothiol (thionitrite) quantification as solution nitrite after vanadium(III) reduction and ozone-chemiluminescent detection. Free Radic. Biol. Med. 25:1998;621-628.
49. Nelin K.D., Hoffman G.M. The use of inhaled nitric oxide in a wide variety of clinical problems. Pediatr. Clin. North Am. 45:1998;531-548.
50. Seki J., Nishio M., Kato Y., Motoyama Y., Yoshida K. FK409, a new nitric oxide-donor, suppressed smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis. 117:1995;97-106.
51. Varenne O., Pislaru S., Jillijns H., Van Pelt N., Gerard R.D., Zoldhelyi P., Van de Werf F., Collen D.L., Janssens S.P. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 98:1998;919-926.
52. Keefer L.K., Nims R.W., Davies K.M., Wink D.A. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors convenient nitric oxide dosage forms . Meth. Enzymol. 268:1996;281-293.
53. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch. Pharmacol. 358:1998;113-122.
54. Ewing J.F., Young D.V., Janero D.R., Garvey D.S., Grinnell T.A. Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. J. Pharmacol. Exp. Ther. 283:1997;947-954.
55. Melman A., Gingell J.C. The epidemiology and pathophysiology of erectile dysfunction. J. Urol. 161:1999;5-11.
56. Burnett A.L., Lowenstein C.J., Bredt D.S., Chang T.S., Snyder S.H. Nitric oxide a physiologic mediator of penile erection . Science. 257:1992;401-403.
57. Juneman K.P. Anatomy of the penis and elementary physiology of erection. Porst H. Penile disorders. 1996;1-12 Springer-Verlag, New York.
58. Glossmann H., Petrischor G., Bartsch G. Molecular mechanisms of the effects of sildenafil (Viagra). Exp. Gerontol. 34:1999;305-318.
59. Welch M. ICOS receives $15M milestone but also has two failed trials. BioWorld Today. 10:1999;1.
60. Shen W.W., Urosevich Z., Clayton D.O. Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. J. Reprod. Med. 44:1999;535-542.
61. 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinepherine. J. Urol. 153:1995;222-227.
62. 1 . Int. J. Impot. Res. 8:1996;41-46.
63. Sáenz de Tejada I., Garvey D.S., Schroeder J.D., Shelekhin T., Letts L.G., Fernández A., Cuevas B., Gabancho S., Martínez V., Angulo J., Trocha M., Marek P., Cuevas P., Tam S.W. Design and evaluation of nitrosylated α- adrenergic receptor antagonists as potential agents for the treatment of impotence. J. Pharmacol. Exp. Ther. 290:1999;121-128.
64. Ellis S.G. Interventions in acute myocardial infarction. Circulation. 81:1990;IV43-IV50.
65. Oesterle S.N. Beyond stents third-generation coronary devices . Ann. Thorac. Surg. 66:1998;1045-1049.
66. Bauters C.T., Eisner J.M. The biology of restenosis. Prog. Cardiovasc. Dis. 40:1997;107-116.
67. Ruygrok P.N., Serruys P.W. Intracoronary stenting. From concept to custom. Circulation. 94:1996;882-890.
68. Lee J.S., Adrie C., Jacob H.J., Roberts J.D. Jr, Zapol W.M., Bloch K.D. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ. Res. 78:1996;337-342.
69. Bosmans J.M., Vrints C.J., Kocks M.M., Bult H., Cromheeke K.M.C., Herman A.G. Continuous perivascular L-arginine delivery increases total vessel area and reduces neointimal thickening after experimental balloon dilatation. Arteriosclero. Thromb. Vasc. Biol. 19:1999;767-776.
70. Marks D.S., Vita J.A., Folts J.D., Keaney J.F. Jr, Welch G.N., Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J. Clin. Invest. 96:1995;2630-2638.
71. LaBlanche J.M., Grollier G., Lusson J.R., Bassand J.-P., Drobinski G., Bertrand B., Battaglia S., Desveaux B., Juilliere Y., Juliard J.-M., Metzger J.-P., Coste P., Quiret J.-C., Dubois-Rande J.-L., Crochet P.D., Letac B., Boschat J., Virot P., Finet G., Le Breton H., Livarek B., Leclercq F., Beard T., Giraud T., McFadden E.P., Bertrand M.E. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study. Circulation. 95:1997;83-89.
72. De Young M.B., Dichek D.A. Gene therapy for restenosis. Are we ready? Circ. Res. 82:1998;306-313.
73. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020 global burden of disease study . Lancet. 349:1997;1498-1504.
74. Pearson S.P., Kelberman I. Gastrointestinal effects of NSAIDs. Difficulties in detection and management. Postgrad. Med. 100:1996;131-143.
75. Wallace J.L. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can. J. Physiol. Pharmacol. 72:1994;1493-1498.
76. Wallace J.L., Grangier N. The cellular and molecular basis of gastric mucosal defense. FASEB J. 10:1996;731-740.
77. Masuda E., Kawanop S., Nagan K., Tsuji S., Takei Y., Tsuji M., Oshita M., Michida T., Kobayashi I., Nakama A., Fusamoto H., Kamada T. Endogenous nitric oxide modulates ethanol-induced gastric mucosal injury in rats. Gastroenterology. 108:1995;58-64.
78. Wallace J.L., Del Soldato P., Cirino G. Nitric oxide-releasing nonsteroidal antiinflammatory drugs a new generation of antithrombotics? Expert Opinion on Investigational Drugs. 6:1997;533-538.
79. Tam, S. W.; Saha, J. K.; Garvey, D. S.; Schroeder, J. D.; Shelekhin, T. E.; Janero, D. R.; Chen, L.; Glavin, A.; Letts, L. G. Nitrosothiol-based NO-donors inhibit gastrointestinal mucosal damaging actions of NSAIDs. Inflammopharmacology In press; 2000.
80. Wallace J.L., Reuter B., Cicalka C., McKnight W., Grisham M., Cirino G. A diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol. 257:1994;249-255.
81. th ACS National Meeting (Medicinal Chem.), New Orleans, LA, August 22-26, 1999 [Abstr.].
82. Mohazzab-H K.M., Kaminski P.M., Agarwal R., Wolin M.S. Potential role of a membrane-bound NADH oxidoreductase in nitric oxide release and arterial relaxation to nitroprusside. Circ. Res. 84:1999;220-228.
83. Singh S.P., Wishnok J.S., Keshive M., Deen W.M., Tannenbaum S.R. The chemistry of the S-nitrosoglutathione/glutathione system. Proc. Natl. Acad. Sci. USA. 93:1996;14428-14433.
84. Saha, J. K.; Bandarage, U.; Janero, D. R.; Chen, L.; Glavin, A.; Garvey, D. S.; Schroeder, J. D.; Letts, L. G.; Tam, S. W. Nitric oxide releasing diclofenac derivative NMI-346 is a novel gastrointestinal sparing NSAID. Gastroenterology 116:A298; 1999. [Abstr.].
85. Fiorucci S., Antonelli E., Santucci L., Morelli O., Miglietti M., Federici B., Mannucci R., Del Soldato P., Morelli A. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology. 116:1999;1089-1106.
86. Welch M. Acquisition allows Apex, shock drug to move ahead. BioWorld Today. 10:1999;1.
87. Etheridge J. NicOx launches $34M IPO to speed up its R&D efforts. BioWorld International. 4:1999;3.
88. NitroMed to Target Black CHF Patients with BiDil. SCRIP Number 2475:3; 1999.
89. Bishop F. NitroMed signs two research pacts with Johnson & Johnson. BioWorld Today. 8:1997;1.
90. Johnson & Johnson/NitroMed Partner to Develop NSAIs. SCRIP Number 2223:15; 1997.
91. Hou Y.C., Janczuk A., Wang P.G. Current trends in the development of nitric oxide donors. Current Pharmaceutical Design. 5:1999;417-441.
92. Drews J. In quest of tomorrow's medicine. 1999;Springer, New York.
93. Drews J. Basic science and pharmaceutical innovation. Nat. Biotechnol. 17:1999;406.
94. NicOx to start first US trials. SCRIP Number 2513:18; 2000.
95. Other News to Note. NicOx SA. BioWorld Today 11:3; 2000.
96. Other News to Note. NicOx SA. BioWorld International 5:4; 2000.